Last reviewed · How we verify
FOL-005
FOL-005 is a Wnt/β-catenin signaling activator designed to stimulate hair follicle growth and treat hair loss.
FOL-005 is a Wnt/β-catenin signaling activator designed to stimulate hair follicle growth and treat hair loss. Used for Androgenetic alopecia (male and female pattern hair loss).
At a glance
| Generic name | FOL-005 |
|---|---|
| Sponsor | Follicum AB |
| Drug class | Wnt/β-catenin pathway activator |
| Target | Wnt/β-catenin signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
FOL-005 works by activating the Wnt/β-catenin signaling pathway, a key developmental pathway involved in hair follicle morphogenesis and growth. By enhancing this pathway, the drug aims to promote hair follicle activation and proliferation, potentially reversing hair loss in androgenetic alopecia and other forms of alopecia.
Approved indications
- Androgenetic alopecia (male and female pattern hair loss)
Common side effects
- Local skin irritation
- Erythema at application site
- Pruritus
Key clinical trials
- A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers (PHASE2)
- To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin (PHASE2)
- Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOL-005 CI brief — competitive landscape report
- FOL-005 updates RSS · CI watch RSS
- Follicum AB portfolio CI